In particular, AMPK activation opposes tumor progression in several cancer types [70] through inhibition of tumor growth-stimulating mammalian Target of Rapamycin (mTOR) [20], and to down-regulation of cyclins and cyclin dependent kinases (CDKs) to inhibit cell-cycle progression [71]. Here, MTOR is linked to neoplasm.